¼¼°èÀÇ DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå ±Ô¸ð¿Í Á¡À¯À² ºÐ¼® : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº° - ¼ö¿ä ¿¹Ãø(-2030³â)
DNA Microarray Market Size and Share Analysis by Type, Application, End User - Global Industry Demand Forecast to 2030
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
½ÃÀåÀÇ °³¿ä
¼¼°èÀÇ DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ »ê¾÷Àº 2023³â¿¡ 19¾ï 8,210¸¸ ´Þ·¯ÀÇ ¸ÅÃâÀ» ´Þ¼ºÇϸç, 2030³â±îÁö 39¾ï 3,080¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ¿¹Ãø ±â°£¿¡ CAGR·Î 10.5%ÀÇ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù.
½ÃÀåÀÇ ¹ßÀüÀº ŽÁö ÇÁ·Î¼¼½º ¹× IT ¼¼°è¿¡¼ ÀÌ ±â¼úÀÇ ÀÎÁöµµ ¹× À̿뵵ÀÇ Çâ»ó, ±×¸®°í ¿©±â¿¡ ÀÌ¿ëÇÏ´Â ¼ÒÇÁÆ®¿þ¾îÀÇ ÁøÈ¿¡ ÀÇÇØ ¼³¸íÇÒ ¼ö ÀÖ½À´Ï´Ù. DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ³ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö·ÎºÎÅÍ Áúº´ Áø´Ü¡¤¸ð´ÏÅ͸µ, ´Ü¹éÁú ¹ßÇö¡¤ÇÁ·ÎÅ׿À¹Í½º µîÀÇ ´Ù¾çÇÑ ¿ëµµ¿¡ ÀÀ¿ëµÇ°í ÀÖ½À´Ï´Ù.
DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â Áø´Ü ¹× ¿¹ÈÄ ¿¹Ãø, Ç¥Àû Ä¡·á ¹× ±âŸ ¿©·¯ Áõ»óÀ» À§ÇØ Æ¯º°È÷ °í¾ÈµÈ °æ·Î·Î ÇöÀçµµ °è¼Ó ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ¿ì¼±, ±âÁ¸ÀÇ Ä¡·á ¹æ¹ýÀ¸·Î´Â Á¤È®ÇÑ Áø´Ü°ú Ä¡·á°¡ ºÒ°¡´ÉÇÕ´Ï´Ù. µû¶ó¼ ¸ÂÃãÇü ÀÇ·á°¡ °í·ÁµÇ°í ÀÖ½À´Ï´Ù.
¾Ï°ú ¸é¿ªÁúȯÀº °Ô³ð¿¡ ´ëÇÑ ¿ÏÀüÇÑ ÀÌÇØ¸¦ ÅëÇØ ¿¹ÈÄ¿Í Ä¡·á¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡´Â °¡Àå À§ÇùÀûÀÎ ÁúȯÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó ¸ÂÃãÇü ÀǷḦ ÁöÁöÇÏ´Â »ç¶÷µéÀÌ ´Ã¾î³ª¸é¼ °ü·Ã »ê¾÷ÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â °Ô³ð ¸ÅÇÎ ¹× ½ÃÄö½Ì °úÁ¤ÀÇ ¸ðµç °÷¿¡¼ Áß¿äÇÑ ÄÄÆ÷³ÍÆ®ÀÔ´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ÃÖ±Ù ¸î ³â°£ÀÇ °íÂû¿¡µµ ºÒ±¸Çϰí, ÀÌ·¯ÇÑ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ¿¬±¸ÀÇ ÀÀ¿ëÀº °¨¿°¼º ÁúȯÀÇ Áø´Ü ¹× °ËÃâ, Áúº´ÀÇ À¯ÀüÀû ±â¹Ý, ¾Ï Áø´Ü, ½Å¾à ¿¬±¸, ¾à¹°À¯ÀüüÇÐ µî¿¡¼ Áõ°¡ÇÏ¿´½À´Ï´Ù.
Áß¿ä °í·Á»çÇ×
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ Ä«Å×°í¸®°¡ 70%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϸç, ºñ¿ë È¿À²¼º°ú Á¤È®ÇÑ À¯ÀüÀÚ ¹ßÇö ¸ð´ÏÅ͸µ ´É·Â¿¡¼ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ÇÏÀ̺긮µåÈ Æ¯À̼ºÀ» ¼±º°ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ´ÜÀÏ¿°±â´ÙÇü¼º(SNP) ¿¬±¸ÀÇ Áß¿äÇÑ ¹æ¹ýÀ¸·Î °£Áֵǰí ÀÖ½À´Ï´Ù.
cDNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ºÎ¹®Àº ¿©·¯ »ý¹°Á¾¿¡ °ÉÄ£ À¯ÀüÀÚ ¹ßÇöÀ» ¿¬±¸ÇÏ´Â µ¥ ÀÖÀ¸¸ç, ÀÌ ±â¼úÀÌ ÇʼöÀûÀ¸·Î Àû¿ëµÊ¿¡ µû¶ó °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
2023³â¿¡´Â Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷ÀÌ 40% ÀÌ»óÀÇ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ½Å¾à °³¹ß ¹× ¿¬±¸ ºÐ¾ß¿¡¼ DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌÀÇ ¼ö¿ëÀÌ È®´ëµÊ¿¡ µû¶ó ÀÌ ºÎ¹®µµ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.
½Å¾à ºÐÀÚ Å½»öÀ» À§ÇÑ ¿¬±¸°³¹ßÀÌ ÀÌ Ä«Å×°í¸®ÀÇ »ê¾÷ ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.
DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ¾Ï ¿¬±¸¿¡¼ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖÀ¸¸ç, ¸¹Àº Àΰ£¾ÏÀ» Áø´ÜÇÒ ¼ö ÀÖ´Â ºÐÀÚ ¸¶Ä¿¸¦ ºÐ·ùÇϰí ÀÖ½À´Ï´Ù.
º´¿ø ¹× Áø´Ü¼¾ÅÍ´Â ÀÓ»ó Áø´Ü¿¡¼ DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â¼úÀÇ ¼ö¿ë¿¡ ÈûÀÔ¾î °¡Àå ºü¸¥ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
÷´Ü ½ÇÇè½Ç¿¡¼´Â DNA ¸¶ÀÌÅ©·Î¾î·¹À̸¦ Ȱ¿ëÇÏ¿© ¹ÙÀÌ¿ÀĨÀ» ÀÌ¿ëÇÑ ÇÑ ¹øÀÇ ºÐ¼®À¸·Î ´Ù¼öÀÇ ´ÙÇü¼ºÀ» °ËÃâÇϰí ÀÖ½À´Ï´Ù.
2023³â ºÏ¹Ì°¡ ¾à 40%ÀÇ Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ ¹ßÀüÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº ±â¼úÀûÀ¸·Î °ÈµÈ DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ¿¡ ÅõÀÚÇÏ´Â ÁÖ¿ä »ê¾÷ ±â¾÷ÀÇ Á¸ÀçÀÔ´Ï´Ù.
ÀÌ ´ë·ú¿¡¼´Â Áø´Ü°ú Ä¡·á°¡ ¾î·Á¿î Áúº´ÀÌ ±ÞÁõÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¸¶ÀÌÅ©·Î¾î·¹ÀÌ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù.
ij³ª´Ù ½ÃÀåÀº ¿ì¼öÇÑ ÀÇ·á ÀÎÇÁ¶ó, ¿Ïº®ÇÑ ´ç´¢º´ Ä¡·á ½ÃÀÛÀ» À§ÇÑ Á¤ºÎ Áö¿ø ½Ã½ºÅÛ, ¸¸¼ºÁúȯÀÇ ±ÞÁõÀ¸·Î ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
ÀÇ·á ºÎ¹®, ƯÈ÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ ¸ÅÃâ ¿ªÇÐÀº ºÏ¹ÌÀÇ Çõ½ÅÀû ÅõÀÚ¿¡ Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù.
¼¼°èÀÇ DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ¿ªÇÐ, Áö¿ª°ú ºÎ¹®º° ½ÃÀå ¸ÅÃâ, °æÀï ±¸µµ µîÀÇ Á¤º¸¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹üÀ§
Á¦2Àå Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå »ê¾÷ÀÇ Àü¹®°¡/KOLÀÇ ¼Ò¸®
Á¦5Àå ½ÃÀåÀÇ ÁöÇ¥
Á¦6Àå »ê¾÷ Àü¸Á
½ÃÀå ¿ªÇÐ
µ¿Çâ
ÃËÁø¿äÀÎ
¾ïÁ¦¿äÀÎ/°úÁ¦
ÃËÁø¿äÀÎ/¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®
COVID-19ÀÇ ¿µÇâ
Porter's Five Forces ºÐ¼®
±â¼ú ºÐ¼®
±ÔÁ¦ ±¸Á¶
Á¦7Àå °æÀï ±¸µµ
½ÃÀå ±â¾÷°ú Á¦°øÇ° ¸®½ºÆ®
ÁÖ¿ä ±â¾÷ÀÇ °æÀï º¥Ä¡¸¶Å·
ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° º¥Ä¡¸¶Å·
ÃÖ±Ù Àü·«Àû ¹ßÀü
Á¦8Àå ¼¼°è ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : Áö¿ªº°(2017-2030³â)
Á¦9Àå ºÏ¹Ì ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)
Á¦10Àå À¯·´ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)
Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)
Á¦12Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)
Á¦13Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ±¹°¡º°(2017-2030³â)
Á¦14Àå ¹Ì±¹ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦15Àå ij³ª´Ù ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦16Àå µ¶ÀÏ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦17Àå ÇÁ¶û½º ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦18Àå ¿µ±¹ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦20Àå ½ºÆäÀÎ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦21Àå Áß±¹ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦22Àå ÀϺ» ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦23Àå Àεµ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦24Àå Çѱ¹ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦25Àå È£ÁÖ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦26Àå ºê¶óÁú ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦27Àå ¸ß½ÃÄÚ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦28Àå »ç¿ìµð¾Æ¶óºñ¾Æ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦29Àå ³²¾ÆÇÁ¸®Ä«°øÈ±¹ ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦30Àå ¾Æ¶ø¿¡¹Ì¸®Æ® ½ÃÀå
°³¿ä
½ÃÀå ¸ÅÃâ : À¯Çüº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ¿ëµµº°(2017-2030³â)
½ÃÀå ¸ÅÃâ : ÃÖÁ¾»ç¿ëÀÚº°(2017-2030³â)
Á¦31Àå ±â¾÷ °³¿ä
Thermo Fisher Scientific Inc.
Agilent Technologies Inc.
Illumina Inc.
F. Hoffmann-La Roche Ltd.
QIAGEN N.V.
Merck KGaA
PerkinElmer Inc.
Applied Microarrays LLC
Savyon Diagnostics
Á¦32Àå ºÎ·Ï
KSA
Market Overview
In 2023, the worldwide DNA microarray industry produced revenue of USD 1,982.1 million, which will attain USD 3,930.8 million by the end of the decade, growing at 10.5% CAGR during the projection period.
The development of this market can be explained by the increase in awareness and use of this technology in the detection process and IT world and, the evolution of software for it. DNA microarray has several applications ranging from agricultural biotechnology to disease diagnosis & monitoring, to protein expression & proteomics, and so on.
DNA microarrays are an ongoing advancement in the specially designed pathway for the very purpose of - diagnosis and prognosis, targeted therapies, and many other conditions. First of all, the treatment methods of the diseases through the traditional way they cannot make the precise diagnosis and treat the disease. Because of that, personalized medicine has come to be considered.
These diseases comprising of cancer and immune disorders are the most threatening of the bunch which bring great implications on each person's prognosis and treatment by considering the acquisition of full genome understanding. Thus, along with this rise in the number of individuals who are in favor of tailored medicine, we can see the expansion of the industry.
The DNA microarray is a crucial component that is everywhere in genome mapping and sequencing processes. However, despite of this quite recent observation, the application of these microarray studies rose in diagnostics and detection of diseases of infectious origin, genetic basis of diseases, cancer diagnostics, new drugs research, pharmacogenomics, etc.
Key Insights
The oligonucleotide DNA microarray category held the largest share, 70%, and is estimated to uphold supremacy because of cost-efficiency and accurate gene expression monitoring abilities.
It has the potential to screen hybridization specificity and therefore is regarded as a key technique for researching single nucleotide polymorphisms (SNPs).
The cDNA microarray segment is projected to record the highest CAGR, given the vital applications of this technology in studying gene expression across several species.
In 2023, the pharmaceutical & biotechnology industry held the largest share, of more than 40%, and the category is also projected to remain dominant because of augmented acceptance of DNA microarrays in drug discovery and research.
Development in research activities for finding new drug molecules supports industry growth in this category.
DNA microarrays are attaining significance in cancer research, classifying molecular markers with diagnostic potential for numerous human cancers.
Hospitals & diagnostic centers will witness the fastest development, propelled by the acceptance of DNA microarray tech in clinical diagnostics.
Advanced laboratories utilize DNA microarrays for detecting numerous polymorphisms in a single assay using biochips.
In 2023, the North American region had a significant share, around 40%, and is forecasted to advance at a strong CAGR.
Major reasons propelling this development include the existence of key industry players investing in technically enhanced DNA microarray items.
The continent witnessed a surge in difficult-to-diagnose and treat diseases, leading to augmented demand for microarrays.
Canada's market is growing rapidly with the boom of superior healthcare infrastructure, government support systems initiating perfect diabetes, and the surge of chronic diseases.
Revenue dynamics in the healthcare sector, in particular biotechnology, are largely influenced by innovative investments in North America.
Table of Contents
Chapter 1. Research Scope
1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
1.4.1. Market size breakdown, by type
1.4.2. Market size breakdown, by application
1.4.3. Market size breakdown, by end user
1.4.4. Market size breakdown, by region
1.4.5. Market size breakdown, by country
1.5. Market Data Reporting Unit
1.6. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.1.1. Paid
2.1.2. Unpaid
2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Market Indicators
Chapter 6. Industry Outlook
6.1. Market Dynamics
6.1.1. Trends
6.1.2. Drivers
6.1.3. Restraints/challenges
6.1.4. Impact analysis of drivers/restraints
6.2. Impact of COVID-19
6.3. Porter's Five Forces Analysis
6.3.1. Bargaining power of buyers
6.3.2. Bargaining power of suppliers
6.3.3. Threat of new entrants
6.3.4. Intensity of rivalry
6.3.5. Threat of substitutes
6.4. Technology Analysis
6.5. Regulatory Framework
Chapter 7. Competitive Landscape
7.1. List of Market Players and their Offerings
7.2. Competitive Benchmarking of Key Players
7.3. Product Benchmarking of Key Players
7.4. Recent Strategic Developments
Chapter 8. Global Market
8.1. Overview
8.2. Market Revenue, by Type (2017-2030)
8.3. Market Revenue, by Application (2017-2030)
8.4. Market Revenue, by End User (2017-2030)
8.5. Market Revenue, by Region (2017-2030)
Chapter 9. North America Market
9.1. Overview
9.2. Market Revenue, by Type (2017-2030)
9.3. Market Revenue, by Application (2017-2030)
9.4. Market Revenue, by End User (2017-2030)
9.5. Market Revenue, by Country (2017-2030)
Chapter 10. Europe Market
10.1. Overview
10.2. Market Revenue, by Type (2017-2030)
10.3. Market Revenue, by Application (2017-2030)
10.4. Market Revenue, by End User (2017-2030)
10.5. Market Revenue, by Country (2017-2030)
Chapter 11. APAC Market
11.1. Overview
11.2. Market Revenue, by Type (2017-2030)
11.3. Market Revenue, by Application (2017-2030)
11.4. Market Revenue, by End User (2017-2030)
11.5. Market Revenue, by Country (2017-2030)
Chapter 12. LATAM Market
12.1. Overview
12.2. Market Revenue, by Type (2017-2030)
12.3. Market Revenue, by Application (2017-2030)
12.4. Market Revenue, by End User (2017-2030)
12.5. Market Revenue, by Country (2017-2030)
Chapter 13. MEA Market
13.1. Overview
13.2. Market Revenue, by Type (2017-2030)
13.3. Market Revenue, by Application (2017-2030)
13.4. Market Revenue, by End User (2017-2030)
13.5. Market Revenue, by Country (2017-2030)
Chapter 14. U.S. Market
14.1. Overview
14.2. Market Revenue, by Type (2017-2030)
14.3. Market Revenue, by Application (2017-2030)
14.4. Market Revenue, by End User (2017-2030)
Chapter 15. Canada Market
15.1. Overview
15.2. Market Revenue, by Type (2017-2030)
15.3. Market Revenue, by Application (2017-2030)
15.4. Market Revenue, by End User (2017-2030)
Chapter 16. Germany Market
16.1. Overview
16.2. Market Revenue, by Type (2017-2030)
16.3. Market Revenue, by Application (2017-2030)
16.4. Market Revenue, by End User (2017-2030)
Chapter 17. France Market
17.1. Overview
17.2. Market Revenue, by Type (2017-2030)
17.3. Market Revenue, by Application (2017-2030)
17.4. Market Revenue, by End User (2017-2030)
Chapter 18. U.K. Market
18.1. Overview
18.2. Market Revenue, by Type (2017-2030)
18.3. Market Revenue, by Application (2017-2030)
18.4. Market Revenue, by End User (2017-2030)
Chapter 19. Italy Market
19.1. Overview
19.2. Market Revenue, by Type (2017-2030)
19.3. Market Revenue, by Application (2017-2030)
19.4. Market Revenue, by End User (2017-2030)
Chapter 20. Spain Market
20.1. Overview
20.2. Market Revenue, by Type (2017-2030)
20.3. Market Revenue, by Application (2017-2030)
20.4. Market Revenue, by End User (2017-2030)
Chapter 21. China Market
21.1. Overview
21.2. Market Revenue, by Type (2017-2030)
21.3. Market Revenue, by Application (2017-2030)
21.4. Market Revenue, by End User (2017-2030)
Chapter 22. Japan Market
22.1. Overview
22.2. Market Revenue, by Type (2017-2030)
22.3. Market Revenue, by Application (2017-2030)
22.4. Market Revenue, by End User (2017-2030)
Chapter 23. India Market
23.1. Overview
23.2. Market Revenue, by Type (2017-2030)
23.3. Market Revenue, by Application (2017-2030)
23.4. Market Revenue, by End User (2017-2030)
Chapter 24. South Korea Market
24.1. Overview
24.2. Market Revenue, by Type (2017-2030)
24.3. Market Revenue, by Application (2017-2030)
24.4. Market Revenue, by End User (2017-2030)
Chapter 25. Australia Market
25.1. Overview
25.2. Market Revenue, by Type (2017-2030)
25.3. Market Revenue, by Application (2017-2030)
25.4. Market Revenue, by End User (2017-2030)
Chapter 26. Brazil Market
26.1. Overview
26.2. Market Revenue, by Type (2017-2030)
26.3. Market Revenue, by Application (2017-2030)
26.4. Market Revenue, by End User (2017-2030)
Chapter 27. Mexico Market
27.1. Overview
27.2. Market Revenue, by Type (2017-2030)
27.3. Market Revenue, by Application (2017-2030)
27.4. Market Revenue, by End User (2017-2030)
Chapter 28. Saudi Arabia Market
28.1. Overview
28.2. Market Revenue, by Type (2017-2030)
28.3. Market Revenue, by Application (2017-2030)
28.4. Market Revenue, by End User (2017-2030)
Chapter 29. South Africa Market
29.1. Overview
29.2. Market Revenue, by Type (2017-2030)
29.3. Market Revenue, by Application (2017-2030)
29.4. Market Revenue, by End User (2017-2030)
Chapter 30. U.A.E. Market
30.1. Overview
30.2. Market Revenue, by Type (2017-2030)
30.3. Market Revenue, by Application (2017-2030)
30.4. Market Revenue, by End User (2017-2030)
Chapter 31. Company Profiles
31.1. Thermo Fisher Scientific Inc.
31.1.1. Business overview
31.1.2. Product and service offerings
31.1.3. Key financial summary
31.2. Agilent Technologies Inc.
31.2.1. Business overview
31.2.2. Product and service offerings
31.2.3. Key financial summary
31.3. Illumina Inc.
31.3.1. Business overview
31.3.2. Product and service offerings
31.3.3. Key financial summary
31.4. F. Hoffmann-La Roche Ltd.
31.4.1. Business overview
31.4.2. Product and service offerings
31.4.3. Key financial summary
31.5. QIAGEN N.V.
31.5.1. Business overview
31.5.2. Product and service offerings
31.5.3. Key financial summary
31.6. Merck KGaA
31.6.1. Business overview
31.6.2. Product and service offerings
31.6.3. Key financial summary
31.7. PerkinElmer Inc.
31.7.1. Business overview
31.7.2. Product and service offerings
31.7.3. Key financial summary
31.8. Applied Microarrays LLC
31.8.1. Business overview
31.8.2. Product and service offerings
31.8.3. Key financial summary
31.9. Savyon Diagnostics
31.9.1. Business overview
31.9.2. Product and service offerings
31.9.3. Key financial summary
Chapter 32. Appendix
32.1. Abbreviations
32.2. Sources and References
32.3. Related Reports